A prospectively validated nomogram for predicting the risk of chemotherapy-induced febrile neutropenia: a multicenter study

Basit Öğe Kaydı
dc.contributor.authorBozcuk, H.
dc.contributor.authorYildiz, M.
dc.contributor.authorArtac, M.
dc.contributor.authorKocer, M.
dc.contributor.authorKaya, C.
dc.contributor.authorUlukal, E.
dc.contributor.authorAy, S.
dc.date.accessioned2024-02-23T13:55:49Z
dc.date.available2024-02-23T13:55:49Z
dc.date.issued2015
dc.departmentNEÜen_US
dc.description.abstractThere is clinical need to predict risk of febrile neutropenia before a specific cycle of chemotherapy in cancer patients. Data on 3882 chemotherapy cycles in 1089 consecutive patients with lung, breast, and colon cancer from four teaching hospitals were used to construct a predictive model for febrile neutropenia. A final nomogram derived from the multivariate predictive model was prospectively confirmed in a second cohort of 960 consecutive cases and 1444 cycles. The following factors were used to construct the nomogram: previous history of febrile neutropenia, pre-cycle lymphocyte count, type of cancer, cycle of current chemotherapy, and patient age. The predictive model had a concordance index of 0.95 (95 % confidence interval (CI) = 0.91-0.99) in the derivation cohort and 0.85 (95 % CI = 0.80-0.91) in the external validation cohort. A threshold of 15 % for the risk of febrile neutropenia in the derivation cohort was associated with a sensitivity of 0.76 and specificity of 0.98. These figures were 1.00 and 0.49 in the validation cohort if a risk threshold of 50 % was chosen. This nomogram is helpful in the prediction of febrile neutropenia after chemotherapy in patients with lung, breast, and colon cancer. Usage of this nomogram may help decrease the morbidity and mortality associated with febrile neutropenia and deserves further validation.en_US
dc.identifier.doi10.1007/s00520-014-2531-6
dc.identifier.endpage1767en_US
dc.identifier.issn0941-4355
dc.identifier.issn1433-7339
dc.identifier.issue6en_US
dc.identifier.pmid25433439en_US
dc.identifier.scopus2-s2.0-84939968926en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage1759en_US
dc.identifier.urihttps://doi.org/10.1007/s00520-014-2531-6
dc.identifier.urihttps://hdl.handle.net/20.500.12452/10969
dc.identifier.volume23en_US
dc.identifier.wosWOS:000353791200034en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofSupportive Care In Canceren_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectFebrile Neutropeniaen_US
dc.subjectNomogramen_US
dc.subjectChemotherapyen_US
dc.subjectBreast Canceren_US
dc.subjectLung Canceren_US
dc.subjectColorectal Canceren_US
dc.titleA prospectively validated nomogram for predicting the risk of chemotherapy-induced febrile neutropenia: a multicenter studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu